ストックスクリーナーアプリを入手
1.18
3.51%
0.04
アフターアワーズ：
1.20
0.02
+1.69%
前日終値:
$1.14
開ける：
$1.14
24時間の取引高:
100.90K
Relative Volume:
0.24
時価総額：
$88.39M
収益：
-
当期純損益:
$-20.59M
株価収益率:
-3.5245
EPS:
-0.3348
ネットキャッシュフロー:
$-17.99M
1週間 パフォーマンス:
-0.84%
1か月 パフォーマンス:
+7.27%
6か月 パフォーマンス:
+0.85%
1年 パフォーマンス:
-31.40%
1日の値動き範囲:
$1.13
$1.18
1週間の範囲:
$1.12
$1.20
52週間の値動き範囲:
$0.8401
$1.75
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-10-06 | 開始されました | Maxim Group | Buy |
| 2021-02-17 | 開始されました | H.C. Wainwright | Buy |
Oncolytics Biotech Inc (ONCY) 最新ニュース
Oncolytics Biotech (TSE:ONC) Shares Pass Above 200-Day Moving AverageShould You Sell? - MarketBeat
Oncolytics Biotech® Announces Fireside Chat at the Cantor Global Healthcare Conference - GuruFocus.com
Oncolytics Biotech Inc. (NASDAQ:ONCY) Sees Significant Increase in Short Interest - MarketBeat
Oncolytics Biotech (TSE:ONC) Shares Cross Above 200-Day Moving AverageShould You Sell? - MarketBeat
Oncolytics Biotech Inc - Stockhouse Publishing
What is Oncolytics Biotech, Inc. (ONCY) Stock Return on Shareholders’ Capital? - SETE News
Oncolytics Biotech (TSE:ONC) Stock Price Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat
Biotech Advances Gain Momentum Amid October’s Rising Breast Cancer Rates and Awareness Efforts - Baystreet.ca
Ratio Analysis: Unpacking Oncolytics Biotech, Inc. (ONCY)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
What was Oncolytics Biotech, Inc. (ONCY)’s performance in the last session? - US Post News
Oncolytic Virus Therapy Market Set to Witness Significant Growth by 2024-2031:Oncolytics Biotech Inc, Circio - EIN News
Stocks In Play: Oncolytics Biotech® Inc. - Barchart
Oncolytics Biotech (NASDAQ:ONCY) Stock Price Down 5.3%Here's Why - MarketBeat
ONCY Stock Up on Regulatory Update From Breast Cancer Program - MSN
A new trading data show Oncolytics Biotech, Inc. (ONCY) is showing positive returns. - SETE News
Quarterly Snapshot: Quick and Current Ratios for Oncolytics Biotech, Inc. (ONCY) - The Dwinnex
Oncolytics Biotech (TSE:ONC) Shares Down 7.9%Here's Why - MarketBeat
Examining Oncolytics Biotech, Inc. (ONCY) more closely is necessary - US Post News
Oncolytics seeking FDA meeting to discuss registration-enabling study - MSN
ONCY’s 52-Week Rollercoaster: From $0.84 to $2.10 – What’s Next for Investors? - The InvestChronicle
Global cancer cases surge while biotech firms accelerate treatment innovations - Benefits and Pensions Monitor
Oncolytics targets accelerated approval for oncolytic virus therapy - Yahoo Finance
Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path - The Malaysian Reserve
Oncolytics Biotech (TSE:ONC) Stock Price Up 11.8%Should You Buy? - MarketBeat
Stocks In Play: Oncolytics Biotech® Inc. By Baystreet.ca - Investing.com Canada
Stocks In Play: Oncolytics Biotech Inc By Baystreet.ca - Investing.com Canada
Oncolytics Biotech® Inc. - Baystreet.ca
Oncolytics Biotech’s Cancer Drug Aims for Fast-Track Approval - TipRanks
FDA Oncology Approvals Accelerate as Global Cancer Rates Set to Climb 77% - Baystreet.ca
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket - Financial Content
FDA Approves 16 New Cancer Treatments As Global Cancer Rates Skyrocket - Barchart
Stocks In Play: Oncolytics Biotech Inc - Barchart
Oncolytics Biotech (TSE:ONC) Hits New 52-Week Low at $1.16 - Defense World
Oncolytics Biotech's SWOT analysis: pela drug potential drives stock outlook By Investing.com - Investing.com Australia
Oncolytics Biotech's SWOT analysis: pelareorep progress lifts stock outlook - Investing.com India
Oncolytics Biotech (TSE:ONC) Reaches New 12-Month Low at $1.20 - Defense World
Promising Progress in Oncology as Cancer Deaths Decline and Research Grows - Baystreet.ca
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase - Benzinga
Global study predicts sharp rise in cancer rates among men by 2050 - Benefits and Pensions Monitor
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs - ForexTV.com
Investors Watch Key Players in Oncology as Cancer Cases Set to Skyrocket - Baystreet.ca
Oncolytics Biotech (TSE:ONC) Given New C$3.50 Price Target at Raymond James - Defense World
Oncolytics Biotech (NASDAQ:ONCY) Receives Buy Rating from HC Wainwright - Defense World
Oncolytics Biotech (TSE:ONC) Price Target Raised to C$3.50 at Raymond James - MarketBeat
Global Cancer Rates Surge as Biotech Innovators Work on New Therapies - cnhinews.com
Abbvie Inc (ABBV-N) QuotePress Release - The Globe and Mail
Recent Breakthroughs in Cancer Research Could Impact These Key Companies - Baystreet.ca
Oncolytics Biotech (NASDAQ:ONCY) Earns Buy Rating from HC Wainwright - MarketBeat
Oncolytics Biotech reports positive results from breast cancer study | 2024-09-19 | Investing News - Stockhouse Publishing
Oncolytics Biotech reports promising breast cancer study results - Investing.com India
Oncolytics Biotech reports promising breast cancer study results By Investing.com - Investing.com Australia
Oncolytics Biotech Inc (ONCY) 財務データ
収益
当期純利益
現金流量
EPS
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):